• Molecular NameFelodipine
  • SynonymDl-Felodipine; Felodipina [INN-Spanish]; felodipine; Felodipine [Usan:Ban:Inn]; Felodipinum [INN-Latin]
  • Weight384.259
  • Drugbank_IDDB01023
  • ACS_NO72509-76-3
  • Show 3D model
  • LogP (experiment)4.8
  • LogP (predicted, AB/LogP v2.0)4.8
  • pkaN/A
  • LogD (pH=7, predicted)4.8
  • Solubility (experiment)0.0197 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-5.33
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors1
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds6
  • TPSA64.63
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA calcium channel blocker (calcium antagonist), a drug used to control hypertension (high blood pressure).
  • Absorption_value90.0
  • Absorption (description)Felodipine is almost completely absorbed after oral administration
  • Caco_2-4.6
  • Bioavailability15.0
  • Protein binding99.6
  • Volume of distribution (VD)10 L/kg (normal patients); 5.6 L/kg (patients with cirrhosis).
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmUndergoes significant CYP3A-dependent first-pass metabolism in the intestine and liver.
  • Half life14 h (oral administration in normal patients); 2 h (patients with renal failure).
  • Excretion70% of a dose is excreted in urine, with < 0.5% unchanged, and the rest in faeces, as metabolites.
  • Urinary Excretion<1
  • Clerance12 ml/min/kg
  • ToxicityThe serum toxic concentration range is 10 to 15 μg/L. Overdosing may cause excessive peripheral vasodilation with marked hypotension and possibly bradycardia.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A